Brainomix widens its lung fibrosis partnership with Boehringer Ingelheim into a multi site study

Lung scarring is usually caught late, and late is the problem. Brainomix says its e-Lung software showed promise at spotting it earlier, and that it and Boehringer Ingelheim are now running a study across many United States sites to find out whether that changes care.

By Atlas ... AI Editorial Collaborator

What Brainomix Announced About the Boehringer Ingelheim Pulmonary Fibrosis Partnership

Brainomix said on 12 May 2026 that it and Boehringer Ingelheim are broadening their partnership in pulmonary fibrosis. The company says the wider agreement builds on early results it describes as showing the potential of its e-Lung software to allow earlier diagnosis of progressive pulmonary fibrosis. It says the next stage, called PROGRESS-PPF, is a forward looking study across several centres designed to produce evidence of the clinical impact of e-Lung at scale, with deployments planned across numerous sites in the United States. The page is a short summary. It names no participating sites, no patient numbers, no timetable and no results.

Why the Brainomix and Boehringer Ingelheim Lung Study Matters to Respiratory Teams

A study that sets out to measure clinical impact is a harder test than the one that came before it, and the company chose to take it. Earlier diagnosis only matters if something changes for the patient, and that is what a prospective multi centre study can show and an early result cannot. Read the wording carefully though. Potential to allow earlier diagnosis is the company describing its own early findings, not a proven result, and this desk has seen no data behind it. There is also a plain commercial reading: the drug company that sells treatment for this condition benefits when more people are found earlier, so the partner funding the evidence has a stake in the answer. That does not make the study wrong. It makes independent sites and published numbers the things to wait for.

Where the Brainomix Update Comes From

Brainomix is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Brainomix original source.

How We Would Research the Brainomix and Boehringer Ingelheim Lung Study

The source gives us the starting point. This is how we would build the next layer of research around it.

We would ask Brainomix for the early results the wider partnership is built on, including how many patients and how earlier diagnosis was measured.
Then we would ask which United States sites are taking part in PROGRESS-PPF and when it reports, because numerous sites is not a list.
We would ask who designed the endpoints and who holds the data, since the partner funding the study also sells treatment for the condition being found.